Author: Wayne Winegarden

Home > Articles posted by Wayne Winegarden

June 22, 2026 Innovation, Policy Proposals, Price and Costs

International drug price comparisons often create more confusion than clarity. One reason: they ignore the large drug access problems that exist in the comparator countries, such as Canada and the U.K. Lost access to drugs raises other health spending and reduces health outcomes. Another fundamental problem is these comparisons rely on U.S. medicines’ gross (or list) price. But list prices do not account for the complex U.S. drug supply chain, where manufacturers receive only a portion of the gross price and...

June 11, 2026 Briefs, Studies

SACRAMENTO – As federal regulators intensify enforcement against companies selling unauthorized knockoffs of blockbuster weight-loss drugs, a new Pacific Research Institute brief warns that the booming GLP-1 knockoff market is creating patient safety risks while undermining future breakthrough medicines. “GLP-1s are among the most promising medical breakthroughs in decades, helping patients struggling with diabetes, obesity and other chronic illnesses,” said Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and Innovation and the brief’s author. “But allowing unauthorized manufacturers to...

April 3, 2026 Blog, Policy Proposals

Dr. Wayne Winegarden, director of PRI's Center for Medical Economics and Innovation, responded to the Trump administration's new plan to impose pharmaceutical tariffs. The Trump administration's new 100% tariff on certain patented pharmaceutical imports will hurt American families. Tariffs are taxes, plain and simple. Doubling the cost of importing many lifesaving medicines will inevitably increase spending for patients, employer-sponsored health plans, and taxpayer-funded insurance programs. At a time when 59% of American adults worry about paying for their medication -- and 19% have...

March 16, 2026 Innovation, Issues

A left-leaning pressure group recently sent a letter to Health and Human Services Secretary Robert F. Kennedy Jr. asking his agency to rescind the patent rights earned by the developers of GLP-1 drugs. Some 12% of U.S. adults have taken these medications. Rescinding the patents is a dangerous idea that would reduce our health and well-being. GLP-1 medications benefit patients with various conditions. They have become a popular weight loss drug that suppresses people’s appetites and helps patients living with Type 2...

February 10, 2026 Briefs, Studies

A new issue brief released today by the Pacific Research Institute—the California-based, nonpartisan, free market think tank—finds that certain states' efforts to tighten corporate practice of medicine laws hurt independent physicians, empower hospitals to consolidate local provider markets, and raise healthcare costs. "Competition is a prerequisite for affordable, high-quality care," said Dr. Wayne Winegarden, the author of the issue brief and Director of the Center for Medical Economics and Innovation at the Pacific Research Institute. "States are understandably concerned about...

November 4, 2025 Briefs, Studies

SACRAMENTO – Proposed reforms to fix the problems with the current Medicare bidding process for acquiring prosthetics, CPAP machines, wheelchairs and other durable medical equipment don’t go far enough to fix the fundamental flaws in the process, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan, California-based, free market think tank, the Pacific Research Institute. Click here to download the brief “Medicare’s current broken bidding process drives up taxpayer costs, promotes the use of...

October 8, 2025 Blog, Policy Proposals, Price and Costs

Sen. Sanders and President Trump are reading from the same playbook. They are trying to address a real problem – the U.S. spends way too much on healthcare – but their playbook misdiagnoses the causes. Consequently, their cures will only worsen the problem. Whether it is Sanders vilifying pharmaceutical companies or Trump’s emphasis on imposing price controls, they both allege that drug spending is a primary driver of the nation’s rising healthcare costs. Even a cursory look at the data demonstrates...

October 1, 2025 Briefs, Policy Proposals, Price and Costs, Studies

SACRAMENTO – As California prepares to restrict access to proven private health insurers for dual eligible Medicare and Medi-Cal patients, the Center for Medical Economics and Innovation at the Pacific Research Institute – the nonpartisan, California-based, free market think tank – today released a new brief showing that expanding competition—not imposing new government restrictions—is the best way to lower costs, expand access, and improve patient outcomes. Download the new brief at www.medecon.org “California mistakenly believes that reducing health care choices will save...

August 4, 2025 Briefs, Industry Trends, Studies

SACRAMENTO – A new issue brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute calls for reforms to expand the reach of the Program of All-Inclusive Care for the Elderly (PACE), a joint Medicare and Medicaid program that delivers comprehensive medical and social care services to lower-income seniors eligible for nursing home-level care so they can live safely at home. Click here to download the brief Expanding PACE’s reach by supporting additional for-profit providers participating...

July 30, 2025 Innovation, Price and Costs

The flaws driving up costs across the broader health care landscape are also driving up the costs for innovative drugs. After all, pharmaceuticals are an integral component used in combination with the broader healthcare system. As a result, spending on medicines both influences and is influenced by the spending on all other healthcare services. Evaluating the total amount of spending on drugs as a share of total healthcare spending provides important perspective, consequently. As Drug Channels notes, “total net drug spending...

July 23, 2025 Price and Costs

The government explicitly grants innovators temporary market exclusivity to provide an opportunity for groundbreaking pharmaceutical companies to recover the costs of capital associated with developing novel treatments. This was one of the express purposes of past federal reform legislation, such as the Hatch-Waxman Act signed in 1984 and the Biologics Price Competition and Innovation Act of 2009 (BPCIA). The reality that, since 2000 alone, 750 new medicines have been developed, demonstrating that these acts are achieving their stated purpose. The pharmaceutical...

July 16, 2025 Price and Costs

Recently, the Federal Trade Commission (FTC) held its first of three listening sessions on the pharmaceutical market. The goal was to discuss reforms that will improve drug affordability by increasing “generic and biosimilar availability” and promoting “competition”. Achieving these goals is essential. The flaw of the first listening session is its focus on the ill-founded claims of “anticompetitive practices” by incumbent manufacturers. This focus demonstrates an inherent misunderstanding of the strengths and flaws of the current pharmaceutical market. Consequently, it will...

June 16, 2025 Blog

International drug price comparisons aren’t just like comparing apples and oranges, they’re like comparing apples and iPhones. That’s because half of brand drug spending in the U.S. goes to PBMs, 340B hospitals and other middlemen, a dynamic that doesn’t exist in other countries. In some instances, the revenues of some U.S. middlemen exceed the total cost of medicines in other countries by as much as 700 percent. I previously highlighted how estimated rebates and fees PBMs receive for 10 commonly used...

June 11, 2025 Briefs, Studies

The Pacific Research Institute’s Center for Medical Economics and Innovation today released a new issue brief warning that continued federal underpayment of doctors is fueling a looming healthcare crisis by accelerating the nation’s physician shortage and undermining access to care. Written by PRI senior fellow in business and economics and CMEI director Dr. Wayne Winegarden, the brief (titled “It’s Time for Medicare to Stop Shortchanging Physicians”) finds that Medicare reimbursement rates are well below market value and have failed to keep...

May 22, 2025 Blog, Price and Costs

To Improve Drug Affordability Congress Should Fix the Payment System President Trump has issued an Executive Order (EO) demanding that drug prices in the U.S. equal the lowest price among comparable industrialized countries. This EO fails to understand the complex drug payment system and threatens to harm patients. Demanding that drug prices in the U.S. equal overseas prices is akin to demanding that the price of all expensive handbags should equal the prices for the knockoffs that people purchase from street vendors. Of...

April 23, 2025 Issues, Price and Costs

At the top of the new executive order’s priorities for pharma is the pill penalty, which Trump said threatens innovation and favors biologics. Currently, small molecule drugs are eligible for price negotiations sooner than biologics — nine years versus 13 years — and critics have said the law disincentivizes small molecule R&D. The order asks Kennedy to work with Congress to end “the distortion that undermines relative investment in small molecule prescription drugs.” “We’re already seeing it where research is being skewed...

April 20, 2025 Innovation, Issues

Surveys confirm that most Americans recognize the value of prescription drugs. But the same surveys also show that Americans are worried that they will be unable to afford needed medicines. These conflicting feelings exemplify the inherent tension when it comes to prescription drugs – how do we incentivize innovation to help patients who lack efficacious treatments while also promoting greater affordability for medicines today? Too often, proposals get this balance between innovation and affordability wrong. Read the entire op-ed. ...

April 7, 2025 Innovation, Issues

Rising demand for long-term care is inevitable as more and more baby boomers retire. Meeting this demand will be a challenge. Recent evidence from the PACE program demonstrates that for-profit care providers can help meet this growing demand, but only if the regulatory environment allows it. Read the entire op-ed here....

March 24, 2025 Blog, Innovation, Price and Costs

An analysis by the American First Policy Institute released today correctly notes that the drug price controls most OECD countries impose on innovative medicines jeopardize future innovations. Yet, while correctly diagnosing their high cost, the authors still recommend that price controls should be imposed on U.S. patients. Adopting such a policy will worsen health outcomes while potentially raising overall healthcare spending even more. The cost of capital for developing a new drug is $2.9 billion, including post approval research and development costs. Meanwhile, the...

February 27, 2025 Briefs, Price and Costs, Studies

SACRAMENTO – Nevada taxpayers could face millions in new bureaucratic costs and patients will likely see less access to life-saving drugs if state government mandates so-called “Maximum Fair Price” price controls on prescription drugs, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan, California-based, free-market think tank, the Pacific Research Institute. “Some Nevada lawmakers want to enact government price controls on prescription drugs in the name of lowering costs for patients,” said Dr....